Home

AMPLY

NOVEL ANTIMICROBIALS FROM NATURAL ENVIRONMENTS


Life finds a way...


AMPLY is a platform that offers both a bioprospecting service (designed to take any form of digital biological data and retrieve novel bioactive and antimicrobial peptides) and a large library of existing compounds that can be leveraged in a variety of biological contexts. 


The AMPLY biolibrary consists of thousands of novel peptides with a wide variety of unique properties: from low-toxicity, variable-spectrum killing of multi-drug resistant clinical bacterial pathogens to the moderation of the gut and skin microbiomes of agricultural and endangered animals to promote growth and health.


With a diverse library of starting compounds alongside an ability to mine novel natural environments AMPY leverages advances in machine learning, ecological and evolutionary genetics, peptide synthesis and bioinformatics to provide a solution-driven approach to locating natural, genetically expressed products. AMPLY can then transform novel prospects into a "powder in a tube" in days, not years. 


The AMPLY bioprospecting and biolibrary services are a practical, high-speed, cost-efficient platform for addressing niche biomedical, animal health, animal nutrition and next-generation packaging needs in industry.



THE AMPLY DISCOVERY CYCLE

SOURCING DATA

Bioprospecting using novel data sources (eukaryotic, prokaryotic, genomic or meta’omic) or mining AMPLY's existing peptide biolibrary. 


 


TESTING

High-throughput diagnostic testing against clinical pathogens (e.g. MRSA) or biologically relevant microbes related to the source data. 



PROSPECT SELECTION

AMPLY mediated annotation and prospect selection via the "Bitpad" - a novel, detailed annotation pipeline designed to highlight bioactive antimicrobial peptides


 


ELUCIDATION

Elucidation of mode of action, structure, and detailed clinical testing (e.g. anti-biofilm & anti-parasitic activity, kill curves, resistance studies)



SYNTHESIS

Bulk peptide synthesis via commercial systhesis partners. Different quality and pricing thresholds allow for focused or wide coverage, from tens to potentially thousands of putative compounds

 


UNDERSTANDING

Biological and evolutionary understanding and contextualisation of newly discovered compounds against existing patented and natural antimicrobials




What are AMPs?

Antimicrobial peptides (AMPs) are evolutionarily ancient weapons; part of the innate immune response found among all classes of life and are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. AMPs have been demonstrated to kill Gram negative and Gram positive bacteria, enveloped viruses, fungi and even transformed or killed cancerous cells. Locating novel AMPs may prove to be a critical therapeutic avenue of the future to aid in the fight against antibiotic resistant bacteria.


AMP detection using tradition pattern-based matching in 'omic datasets can return limited results. Detection often relies on a “balance of proof” and complex comparisons across a variety of analysis techniques. AMPLY is a tool designed to identify AMPs by separating them from 'omic “background noise”. At the heart of AMPLY are multiple detection engines which characterise prospective peptides with potentially desirable properties. A comparative presentation dashboard allows the end user to rapidly assess these identified prospects and determine their suitability for synthesis and lab testing.



The AMPLY Team

AMPLY is a service/compound library provided by Ben Thomas a postdoctoral researcher supported by Aberystwyth University (Wales, UK), Queen's University (Belfast, UK) and is part of Prof. Chris Creevey's Creevey Lab (creeveylab.org). Funding for the tool comes from Life Science Research Network Wales, Aberystwyth University and Queen's University. Key peptide synthesis partners are St. George's University Hospital London (Tika Diagnostics) and Genscript, HK. 


The photo on this page is provided by Jurnorain Gani (via the St. George's Univeristy, London maging facility) and shows E. coli bacteria being killed after 10 minutes exposure to a novel AMP identified by the AMPLY pipeline. All images and text on these pages is copyright and should not be reproduced without permission.